Antiplatelet activity of J78 (2-chloro-3-[2′-bromo, 4′-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 1, 2005, Pages 214-219

  Jin, Yong Ri ^a   Cho, Mi Ra ^a   Ryu, Chung Kyu ^b   Chung, Jin Ho ^c   Yuk, Dong Yeon ^a   Hong, Jin Tae ^a   Lee, Kyung Sup ^a   Lee, Jung Jin ^a   Lee, Mi Yea ^a   Lim, Yong ^a   Yun, Yeo Pyo ^a  

^a Chungbuk National University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 CHLORO 3 (2' BROMO 4' FLUORO PHENYL)AMINO 8 HYDROXY 1,4 NAPHTHOQUINONE; ANTICOAGULANT AGENT; ARACHIDONIC ACID; CALCIUM ION; COLLAGEN; J 78; PROSTAGLANDIN D2; PROSTAGLANDIN H2; THROMBIN; THROMBOXANE A2 RECEPTOR; THROMBOXANE B2; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; IC 50; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ANIMALS; ARACHIDONIC ACID; BLOOD PLATELETS; CALCIUM; COLLAGEN; MALE; NAPHTHOQUINONES; PLATELET AGGREGATION; PROSTAGLANDINS D; RABBITS; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE-A SYNTHASE;

EID: 19944429965     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.073718     Document Type: Article

References (31)

1. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 89:588-595.
2. Awtry EH and Loscalzo J (2000) Aspirin. Circulation 101:1206-1218.
3. Balsinde J, Winstead MV, and Dennis EA (2002) Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 531:2-6.
4. Born GV and Cross MJ (1963) The aggregation of blood platelets. J Physiol 168: 178-195.
5. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, and FitzGerald GA (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809-1817.
6. 2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets. Biochem Pharmacol 54:259-268.
7. Chang YS, Kuo SC, Weng SH, Jan SC, Ko FN, and Teng CM (1993) Inhibition of platelet aggregation by shikonin derivatives isolated from Arnebia euchroma. Planta Med 59:401-404.
8. Chen X, Yang L, Oppenheim JJ, and Howard MZ (2002) Cellular pharmacology studies of shikonin derivatives. Phytother Res 16:199-209.
9. 2. Science (Wash DC) 296:539-541.
10. Colman R, Cook J, and Niewiarowski S (1994) Hemostasis and Thrombosis, J.B. Lippincott Company, Philadelphia, PA.
11. Corti R, Farkouh ME, and Badimon JJ (2002) The vulnerable plaque and acute coronary syndromes. Am J Med 113:668-680.
12. Corti R, Fuster V, and Badimon JJ (2003) Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 41:7S-14S.
13. Coto V, Cocozza M, Oliviero U, Lucariello A, Picano T, Coto F, and Cacciatore L (1989) Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 40:880-885.
14. Coto V, Oliviero U, Cocozza M, and Milani M (1998) Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study. J Int Med Res 26:200-205.
15. Farndale RW, Sixma JJ, Barnes MJ, and De Groot PG (2004) The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2:561-573.
16. Fitzgerald DJ, Roy L, Catella F, and FitzGerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983-989.
17. Hoet B, Arnout J, Van Geet C, Deckmyn H, Verhaeghe R, and Vermylen J (1990) Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemost 64:87-90.
18. Jackson SP, Nesbitt WS, and Kulkarni S (2003) Signaling events underlying thrombus formation. J Thromb Haemost 1:1602-1612.
19. Jin YR, Ryu CK, Moon CK, Cho MR, and Yun YP (2004) Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation. Pharmacology 70:195-200.
20. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, and Francis GS (2003) Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med 163:1145-1153.
21. Kang WS, Chung KH, Chung JH, Lee JY, Park JB, Zhang YH, Yoo HS, and Yun YP (2001) Antiplatelet activity of green tea catechins is mediated by inhibition of cytosolic calcium increase. J Cardiovasc Pharmacol 38:875-884.
22. Kim HS, Zhang YH, and Yun YP (1999) Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation. Planta Med 65:135-138.
23. Lapetina EG (1990) The signal transduction induced by thrombin in human platelets. FEBS Lett 268:400-404.
24. Lien JC, Huang LJ, Teng CM, Wang JP, and Kuo SC (2002) Synthesis of 2-alkoxy 1,4-naphthoquinone derivatives as antiplatelet, antiinflammatory and antiallergic agents. Chem Pharm Bull (Tokyo) 50:672-674.
25. Miyamoto M, Yamada N, Ikezawa S, Ohno M, Otake A, Umemura K, and Matsushita T (2003) Effects of TRA-418, a novel TP-receptor antagonist and IP-receptor agonist, on human platelet activation and aggregation. Br J Pharmacol 140:889-894.
26. Neirotti M, Molaschi M, Ponzetto M, Macchione C, Poli L, Bonino F, and Fabris F (1994) Hemodynamic, hemorheologic and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs. Angiology 45:137-141.
27. 2 receptor interaction. J Pharmacol Exp Ther 228:240-244.
28. Rolin S, Dogne JM, Michaux C, Delarge J, and Masereel B (2001) Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostag Leukotr Ess 65:67-72.
29. 2+ signaling. Biochem Pharmacol 58:1167-1172.
30. Son DJ, Cho MR, Jin YR, Kim SY, Park YH, Lee SH, Akiba S, Sato T, and Yun YP (2004) Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostag Leukotr Ess 71:25-31.
31. Wang JP and Kuo SC (1997) Impairment of phosphatidylinositol signaling in acetylshikonin-treated neutrophils. Biochem Pharmacol 53:1173-1177.